Pharmacokinetic scaling of SJ-8029, a novel anticancer agent possessing microtubule and topoisomerase inhibiting activities, by species-invariant time methods-Reference-Cited by-同舟云学术

Pharmacokinetic scaling of SJ-8029, a novel anticancer agent possessing microtubule and topoisomerase inhibiting activities, by species-invariant time methods

Published:2003 Issue:5 Volume:24 Page:191-197
ISSN:0142-2782
Container-title:Biopharmaceutics & Drug Disposition
language:en
Short-container-title:Biopharm. Drug Dispos.

Author:

Shin Beom S.,Kim Dong H.,Cho Chang Y.,Park Si K.,Chung Sun G.,Cho Eui H.,Lee Sun H.,Joo Jeong H.,Kwon Ho S.,Lee Kang C.,Yoo Sun D.

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science,Pharmacology,General Medicine

Reference12 articles.

1. et al. 9-Aminoacridine derivatives and process for the preparation thereof. PCT/KR02/00392, March 3, 2002.

2. Yeast cells expressing differential levels of human or yeast DNA topoisomerase II: a potent tool for identification and characterization of topoisomerase II-targeting antitumour agents

3. Exploiting mechanistic differences between drug classes to define functional drug interaction domains on topoisomerase II. Evidence that several diverse DNA cleavage-enhancing agents share a common site of action on the enzyme

4. ANALYSIS AND STABILITY OF A NOVEL ANTICANCER AGENT, SJ-8029, POSSESSING MICROTUBULE AND TOPOISOMERASE INHIBITING ACTIVITIES

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Model-based drug development: application of modeling and simulation in drug development;Journal of Pharmaceutical Investigation;2017-12-27

2. Pharmacokinetic scaling of epirubicin using allometric and species-invariant time methods;Journal of Pharmaceutical Investigation;2015-08-08

3. Interspecies difference of luteolin and apigenin after oral administration of Chrysanthemum morifolium extract and prediction of human pharmacokinetics;PHARMAZIE;2013

4. Toxicokinetics: A Guidance for Assessing Systemic Exposure in Toxicology Studies, Where Are We Now; An S3A/S3B Update (1995–2011);Global Approach in Safety Testing;2013

5. Preclinical Pharmacokinetics of MI-219, a Novel Human Double Minute 2 (HDM2) Inhibitor and Prediction of Human Pharmacokinetics;Journal of Pharmacy & Pharmaceutical Sciences;2012-04-11